Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes
1. Introduction
2. Bioinformatics and Drug Repurposing
3. Impact of Vaccines
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Avanzato, V.A.; Matson, M.J.; Seifert, S.N.; Pryce, R.; Williamson, B.N.; Anzick, S.L.; Barbian, K.; Judson, S.D.; Fischer, E.R.; Martens, C.; et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020, 183, 1901–1912.e9. [Google Scholar] [CrossRef]
- Choi, B.; Choudhary, M.C.; Regan, J.; Sparks, J.A.; Padera, R.F.; Qiu, X.; Solomon, I.H.; Kuo, H.-H.; Boucau, J.; Bowman, K.; et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N. Engl. J. Med. 2020, 383, 2291–2293. [Google Scholar] [CrossRef]
- Corey, L.; Beyrer, C.; Cohen, M.S.; Michael, N.L.; Bedford, T.; Rolland, M. SARS-CoV-2 Variants in Patients with Immunosuppression. N. Engl. J. Med. 2021, 385, 562–566. [Google Scholar] [CrossRef] [PubMed]
- Bajaj, V.; Gadi, N.; Spihlman, A.P.; Wu, S.C.; Choi, C.H.; Moulton, V.R. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front. Physiol. 2021, 11, 571416. [Google Scholar] [CrossRef] [PubMed]
- Feehan, J.; Tripodi, N.; Apostolopoulos, V. The twilight of the immune system: The impact of immunosenescence in aging. Maturitas 2021, 147, 7–13. [Google Scholar] [CrossRef] [PubMed]
- Fung, M.; Babik, J.M. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. 2020, 72, 340–350. [Google Scholar] [CrossRef]
- Mueller, A.L.; McNamara, M.S.; Sinclair, D.A. Why does COVID-19 disproportionately affect older people? Aging 2020, 12, 9959–9981. [Google Scholar] [CrossRef]
- Feehan, J.; Apostolopoulos, V. Is COVID-19 the worst pandemic? Maturitas 2021, 149, 56–58. [Google Scholar] [CrossRef]
- Schultze, J.L.; Aschenbrenner, A.C. COVID-19 and the human innate immune system. Cell 2021, 184, 1671–1692. [Google Scholar] [CrossRef]
- Bhattacharyya, R.P.; Hanage, W.P. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. N. Engl. J. Med. 2022, 386, e14. [Google Scholar] [CrossRef]
- Chavda, V.P.; Apostolopoulos, V. Omicron Variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly? Maturitas 2022, 158, P78–P81. [Google Scholar] [CrossRef]
- Chavda, V.P.; Vora, L.K.; Pandya, A.K.; Patravale, V.B. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov. Today 2021, 26, 2619–2636. [Google Scholar] [CrossRef]
- Chavda, V.P.; Patel, A.B.; Vaghasiya, D.D. SARS-CoV-2 variants and vulnerability at the global level. J. Med. Virol. 2022, 94, 2986–3005. [Google Scholar] [CrossRef]
- Chavda, V.P.; Apostolopoulos, V. Global impact of delta plus variant and vaccination. Expert Rev. Vaccines 2022, 21, 597–600. [Google Scholar] [CrossRef]
- Chavda, V.P.; Ghali, E.N.H.K.; Yallapu, M.M.; Apostolopoulos, V. Therapeutics to tackle Omicron outbreak. Immunotherapy 2022, 14, 833–838. [Google Scholar] [CrossRef]
- Huang, Z.; Chavda, V.P.; Vora, L.K.; Gajjar, N.; Apostolopoulos, V.; Shah, N.; Chen, Z.-S. 2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update. Front. Pharmacol. 2022, 13, 899633. [Google Scholar] [CrossRef]
- Chavda, V.P.; Apostolopoulos, V. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2? Vaccines 2022, 10, 367. [Google Scholar] [CrossRef]
- Mahase, E. COVID-19: What do we know about omicron sublineages? BMJ 2022, 376, o358. [Google Scholar] [CrossRef]
- Chavda, V.P.; Gajjar, N.; Shah, N.; Dave, D.J. Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. Eur. J. Med. Chem. Rep. 2021, 3, 100013. [Google Scholar] [CrossRef]
- Chavda, V.P.; Kapadia, C.; Soni, S.; Prajapati, R.; Chauhan, S.C.; Yallapu, M.M.; Apostolopoulos, V. A global picture: Therapeutic perspectives for COVID-19. Immunotherapy 2022, 14, 351–371. [Google Scholar] [CrossRef]
- Chavda, V.P.; Hossain, K.; Beladiya, J.; Apostolopoulos, V. Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. Biologics 2021, 1, 337–356. [Google Scholar] [CrossRef]
- Chavda, V.P.; Patel, A.B.; Vihol, D.; Vaghasiya, D.D.; Ahmed, K.M.S.B.; Trivedi, K.U.; Dave, D.J. Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update. Clin. Complement. Med. Pharmacol. 2022, 2, 100021. [Google Scholar] [CrossRef]
- Chavda, V.P.; Bezbaruah, R.; Athalye, M.; Parikh, P.K.; Chhipa, A.S.; Patel, S.; Apostolopoulos, V. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses 2022, 14, 759. [Google Scholar] [CrossRef]
- Krishnan, A.; Gangadaran, P.; Chavda, V.P.; Jogalekar, M.P.; Muthusamy, R.; Valu, D.; Vadivalagan, C.; Ramani, P.; Laishevtcev, A.; Katari, N.K.; et al. Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery. Exp. Biol. Med. 2022, 13, 15353702221092984. [Google Scholar] [CrossRef]
- Chavda, V.P.; Vora, L.K.; Vihol, D.R. COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals. Clin. Complement. Med. Pharmacol. 2021, 1, 100004. [Google Scholar] [CrossRef]
- Basu, D.; Chavda, V.P.; Mehta, A.A. Therapeutics for COVID-19 and post COVID-19 complications: An update. Curr. Res. Pharmacol. Drug Discov. 2022, 3, 100086. [Google Scholar] [CrossRef]
- Chavda, V.; Feehan, J.; Apostolopoulos, V. A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals. Vaccines 2021, 9, 631. [Google Scholar] [CrossRef]
- Gadanec, L.; McSweeney, K.; Qaradakhi, T.; Ali, B.; Zulli, A.; Apostolopoulos, V. Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells? Int. J. Mol. Sci. 2021, 22, 992. [Google Scholar] [CrossRef]
- Russo, P.; Tacconelli, E.; Olimpieri, P.P.; Celant, S.; Colatrella, A.; Tomassini, L.; Palù, G. Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. Viruses 2022, 14, 1197. [Google Scholar] [CrossRef]
- Ridgway, H.; Chasapis, C.T.; Kelaidonis, K.; Ligielli, I.; Moore, G.J.; Gadanec, L.K.; Zulli, A.; Apostolopoulos, V.; Mavromoustakos, T.; Matsoukas, J.M. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Viruses 2022, 14, 1029. [Google Scholar] [CrossRef]
- Burki, T. The future of Paxlovid for COVID-19. Lancet Respir. Med. 2022, 10, e68. [Google Scholar] [CrossRef]
- Hassanzadeganroudsari, M.; Ahmadi, A.; Rashidi, N.; Hossain, K.; Habib, A.; Apostolopoulos, V. Computational Chemistry to Repurposing Drugs for the Control of COVID-19. Biologics 2021, 1, 111–128. [Google Scholar] [CrossRef]
- Chavda, V.P.; Ertas, Y.N.; Walhekar, V.; Modh, D.; Doshi, A.; Shah, N.; Anand, K.; Chhabria, M. Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds. Front. Pharmacol. 2021, 12, 702611. [Google Scholar] [CrossRef] [PubMed]
- Chavda, V.; Sheta, S.; Changani, D.; Chavda, D. New Bioinformatics Platform-Based Approach for Drug Design. In Computation in Bioinformatics: Multidisciplinary Applications; Scrivener Publishing LLC: Beverly, MA, USA, 2021; pp. 101–120. [Google Scholar] [CrossRef]
- Sahoo, B.M.; Ravi Kumar, B.V.V.; Sruti, J.; Mahapatra, M.K.; Banik, B.K.; Borah, P. Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection. Front. Mol. Biosci. 2021, 8, 628144. [Google Scholar] [CrossRef]
- Chavda, V.P.; Prajapati, R.; Lathigara, D.; Nagar, B.; Kukadiya, J.; Redwan, E.M.; Uversky, V.N.; Kher, M.N.; Patel, R. Therapeutic monoclonal antibodies for COVID-19 management: An update. Expert Opin. Biol. Ther. 2022, 22, 763–780. [Google Scholar] [CrossRef]
- Chavda, V.P. Nanobased Nano Drug Delivery: A Comprehensive Review. In Applications of Targeted Nano Drugs and Delivery Systems; Mohapatra, S.S., Ranjan, S., Dasgupta, N., Mishra, R.K., Eds.; Elsevier: Amsterdam, The Netherlands, 2019; Chapter 4; pp. 69–92. [Google Scholar] [CrossRef]
- Chavda, V.P. Nanotherapeutics and Nanobiotechnology. In Applications of Targeted Nano Drugs and Delivery Systems; Elsevier: Amsterdam, The Netherlands, 2019; pp. 1–13. [Google Scholar]
- Chen, R.-P.; Chavda, V.P.; Patel, A.B.; Chen, Z.-S. Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines. Front. Pharmacol. 2022, 13, 850862. [Google Scholar] [CrossRef]
- Chavda, V.P.; Patel, A.B.; Mistry, K.J.; Suthar, S.F.; Wu, Z.-X.; Chen, Z.-S.; Hou, K. Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges. Front. Oncol. 2022, 12, 867655. [Google Scholar] [CrossRef]
- Chavda, V.P.; Vihol, D.; Mehta, B.; Shah, D.; Patel, M.; Vora, L.K.; Pereira-Silva, M.; Paiva-Santos, A.C. Phytochemical-loaded liposomes for anticancer therapy: An updated review. Nanomedicine 2022, 17, 547–568. [Google Scholar] [CrossRef]
- Hossain, K.; Hassanzadeganroudsari, M.; Feehan, J.; Apostolopoulos, V. The race for a COVID-19 vaccine: Where are we up to? Expert Rev. Vaccines 2021, 21, 355–376. [Google Scholar] [CrossRef]
- Cohn, B.A.; Cirillo, P.M.; Murphy, C.C.; Krigbaum, N.Y.; Wallace, A.W. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 2022, 375, 331–336. [Google Scholar] [CrossRef]
- Sheikh, A.; Robertson, C.; Taylor, B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. N. Engl. J. Med. 2021, 385, 2195–2197. [Google Scholar] [CrossRef]
- Kaur, R.J.; Dutta, S.; Bhardwaj, P.; Charan, J.; Dhingra, S.; Mitra, P.; Singh, K.; Yadav, D.; Sharma, P.; Misra, S. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J. Clin. Biochem. 2021, 36, 427–439. [Google Scholar] [CrossRef]
- Ali, N. Relationship Between COVID-19 Infection and Liver Injury: A Review of Recent Data. Front. Med. 2020, 7, 458. [Google Scholar] [CrossRef]
- Fasano, G.; Bennardo, L.; Ruffolo, S.; Passante, M.; Ambrosio, A.G.; Napolitano, M.; Provenzano, E.; Nisticò, S.P.; Patruno, C. Erythema Migrans-like COVID Vaccine Arm: A Literature Review. J. Clin. Med. 2022, 11, 797. [Google Scholar] [CrossRef]
- Petruzzi, M.; Galleggiante, S.; Messina, S.; della Vella, F. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: A report of four cases. BMC Oral Health 2022, 22, 90. [Google Scholar] [CrossRef]
- Gargano, J.W.; Wallace, M.; Hadler, S.C.; Langley, G.; Su, J.R.; Oster, M.E.; Broder, K.R.; Gee, J.; Weintraub, E.; Shimabukuro, T.; et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices—United States, June 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 977–982. [Google Scholar] [CrossRef]
- Bhuyan, P.; Medin, J.; da Silva, H.G.; Yadavalli, M.; Shankar, N.K.; Mullerova, H.; Arnold, M.; Nord, M. Very rare thrombosis with thrombocytopenia after second AZD1222 dose: A global safety database analysis. Lancet 2021, 398, 577–578. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chavda, V.P.; Chhabria, M.T.; Apostolopoulos, V. Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes. Biologics 2022, 2, 165-170. https://doi.org/10.3390/biologics2030013
Chavda VP, Chhabria MT, Apostolopoulos V. Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes. Biologics. 2022; 2(3):165-170. https://doi.org/10.3390/biologics2030013
Chicago/Turabian StyleChavda, Vivek P., Mahesh T. Chhabria, and Vasso Apostolopoulos. 2022. "Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes" Biologics 2, no. 3: 165-170. https://doi.org/10.3390/biologics2030013